Overview

A Phase 1 Safety Study of the Intravenous Administration of Thymosin Beta in Healthy Volunteers

Status:
Withdrawn
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether the intravenous administration of single- and multiple-ascending doses of Thymosin Beta 4 is safe and tolerable in healthy volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
RegeneRx Biopharmaceuticals, Inc.